SOURCE: PLC Systems, Inc.

July 10, 2013 08:15 ET

PLC Systems Expands Its Suite of Corporate Communication Channels

Launches Company Blog and Introduces New Executive Video

MILFORD, MA--(Marketwired - July 10, 2013) - PLC Systems Inc. (OTCQB: PLCSF), a company focused on innovative medical device technologies, today announced the launch of a featured profile on and a new Executive Video featuring President & CEO, Mark R. Tauscher.

The Chairman's Blog is an online communication portal where PLC executives will be able to address important topics on the prevention of acute kidney injury (AKI) as it relates to certain cardiac and vascular imaging procedures, as well as specific points of discussion relative to key events at PLC. President & CEO Mark Tauscher penned the Company's inaugural blog post entitled, "Welcome to the PLC Blog." The blog post can be found on the PLC's featured page on The Chairman's Blog,

In the Executive Video, Mr. Tauscher reviews the Company's strategy and vision for its lead product, RenalGuard®. The video is available on the Company's website at

About PLC Systems Inc.
PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing Contrast-Induced Acute Kidney Injury (CI-AKI). RenalGuard is being studied in a pivotal trial in the U.S., as part of the FDA approval process. For more information, visit, or connect with the Company on Facebook, Twitter, LinkedIn, YouTube and Google+.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2012, a copy of which is on file with the SEC.

Contact Information